Cantor Fitzgerald Issues Positive Outlook for BBIO Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for BridgeBio Pharma to ($3.57), up from a previous estimate of ($3.93), maintaining an "Overweight" rating with a target price of $95.00.
• BridgeBio Pharma reported a quarterly loss of ($0.95) per share, missing the consensus estimate of ($0.83), but achieved a significant revenue increase of 4999.9% year-over-year.
• The average rating for BridgeBio Pharma among analysts is a "Moderate Buy" with an average price target of $61.35, despite fluctuations in stock performance and recent insider sales.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of BridgeBio Pharma in a research note issued on Wednesday, August 6th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($3.57) per share for the year, up from their prior estimate of ($3.93). Cantor Fitzgerald currently has a "Overweight" rating and a $95.00 target price on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Cantor Fitzgerald also issued estimates for BridgeBio Pharma's FY2026 earnings at ($2.59) EPS.

A number of other equities analysts have also recently weighed in on the company. Truist Financial began coverage on BridgeBio Pharma in a report on Monday, July 21st. They issued a "buy" rating and a $66.00 price target for the company. Wall Street Zen upgraded BridgeBio Pharma from a "sell" rating to a "hold" rating in a research note on Saturday. Wells Fargo & Company increased their target price on BridgeBio Pharma from $67.00 to $76.00 and gave the company an "overweight" rating in a research note on Monday, June 30th. Citigroup increased their target price on BridgeBio Pharma from $58.00 to $67.00 and gave the company a "buy" rating in a research note on Friday, July 11th. Finally, Oppenheimer increased their target price on BridgeBio Pharma from $60.00 to $61.00 and gave the company an "outperform" rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and a consensus target price of $61.35.

BridgeBio Pharma Price Performance

NASDAQ BBIO traded up $0.63 on Friday, reaching $46.58. The company had a trading volume of 2,498,017 shares, compared to its average volume of 2,964,618. The firm has a market capitalization of $8.90 billion, a PE ratio of -11.39 and a beta of 1.23. BridgeBio Pharma has a 1 year low of $21.72 and a 1 year high of $49.77. The firm has a 50-day moving average of $43.66 and a 200-day moving average of $37.48.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The business had revenue of $110.57 million during the quarter, compared to analysts' expectations of $98.46 million. The firm's revenue for the quarter was up 4999.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.39) EPS.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Frank Mccormick sold 100,000 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $44.23, for a total value of $4,423,000.00. Following the sale, the director directly owned 879,979 shares of the company's stock, valued at $38,921,471.17. This trade represents a 10.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Andrea Ellis sold 17,167 shares of the firm's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $49.00, for a total value of $841,183.00. Following the transaction, the director directly owned 18,589 shares in the company, valued at $910,861. This trade represents a 48.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,767,322 shares of company stock valued at $369,921,586 over the last three months. 18.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BBIO. Legal & General Group Plc increased its holdings in shares of BridgeBio Pharma by 2.8% during the fourth quarter. Legal & General Group Plc now owns 134,038 shares of the company's stock valued at $3,678,000 after purchasing an additional 3,706 shares during the period. Raymond James Financial Inc. bought a new position in BridgeBio Pharma during the fourth quarter valued at about $456,000. F M Investments LLC bought a new position in BridgeBio Pharma during the fourth quarter valued at about $2,667,000. Sterling Capital Management LLC boosted its stake in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after buying an additional 1,514 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in BridgeBio Pharma by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company's stock valued at $404,000 after buying an additional 466 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.